Predicting systemic therapy toxicity in older adult patients with advanced non-small cell lung cancer: A prospective multicenter study of National Hospital Organization in Japan. Issue 8 (November 2022)

• Record Type: Journal Article
• Authors: Kanazu, Masaki; Shimokawa, Mototsugu; Saito, Ryusei; Mori, Masahide; Tamura, Atsuhisa; Okano, Yoshio; Fujita, Yuka; Endo, Takeo; Motegi, Mitsuru; Takata, Shohei; Kita, Toshiyuki; Sukoh, Noriaki; Takenoyama, Mitsuhiro; Atagi, Shinji
• Is Part Of: Journal of geriatric oncology. Volume 13:Issue 8(2022)
• Page Start: 1216
• Page End: 1222
• Publication Date: 2022-11
• Subjects: Systemic therapy toxicity -- Older adult patients -- Non-small cell lung cancer -- Predictive model -- Risk stratification; Geriatric oncology -- Periodicals; Neoplasms -- Periodicals; Aged -- Periodicals; Geriatric oncology; Electronic journals; Periodicals; 618.976994005
• DOI: 10.1016/j.jgo.2022.07.011
• Languages: English
• ISSNs: 1879-4068

Abstract

Abstract: Introduction: Previous studies have developed risk stratification schemas to assess systemic therapy toxicity. However, it is controversial which geriatric assessment variables should be used to assess the individual risk of severe treatment-associated toxicity in older adult patients. Materials and methods: Patients aged ≥70 years with advanced non-small cell lung cancer (NSCLC) treated at 24 National Hospital Organization institutions completed a pre-first-line systemic therapy assessment, including patient characteristics, treatment variables, laboratory test values, and geriatric assessment variables. Patients were followed through one cycle of systemic therapy to assess grade 3 (severe) to grade 5 (death) adverse events according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Results: In total, 348 advanced NSCLC patients with a median age of 76 years (range, 70 to 95 years) joined this prospective study. Severe adverse events ≥grade 3 occurred in 136 patients (39.1%). Predictors of hematologic toxicity were treatment variables, body mass index, body weight loss, and limitation in daily living due to dementia. These predictors provided the predictive model of hematologic toxicity ≥grade 3; 0 point (22.2%), 1 point (33.8%), 2 points (59.6%), ≥3 points (73.3%). Sex, daily living independence level, and lactate dehydrogenase levels were associated with non-hematologic toxicity ≥grade 3 in multivariate analysis. A scoring system using these predictors distinguished the risk levels of non-hematologic toxicity ≥grade 3; 0 point (6.6%), 1 point (12.2%), 2 points (39.0%), 3 points (75.0%). Discussion: A stratification using individual extracted risk factors may be useful to predict the vulnerability to systemic therapy in older adult NSCLC patients.